10x Genomics, Inc. reaffirmed revenue guidance for the year 2024. The company maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.96 USD | +0.96% |
|
+1.22% | -64.33% |
Jun. 03 | Jefferies Initiates 10x Genomics at Hold Rating With $24 Price Target | MT |
May. 29 | 10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.33% | 2.37B | |
-10.93% | 11.41B | |
-11.84% | 7.53B | |
+31.42% | 5.62B | |
+4.38% | 5.54B | |
-17.33% | 3.82B | |
+7.01% | 2.6B | |
-10.17% | 2.26B | |
+24.35% | 2.16B | |
-12.83% | 1.71B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024